A Prospective, Multicenter, Randomized Controlled Study on the Efficacy and Safety of Low-dose Carboplatin Combined With Nab-Paclitaxel and Delayed Administration of Serplulimab as First-line Treatment for Advanced Squamous Non-small Cell Lung Cancer

NCT07647094 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

112

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Serplulimab, Nab-Paclitaxel, Carboplatin

Sponsor

People's Hospital of Quzhou